In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Public-Private Partnerships Like IMI Crucial to Industry's Future, Argue Leaders

Executive Summary

Public-private partnerships like Europe's Innovative Medicines Initiative, the EU’s mechanism that promotes new treatment R&D, are crucial to the industry's future, according to Paul Stoffels, Chairman global R&D pharmaceuticals at Johnson & Johnson.
Advertisement

Related Content

EFPIA Urges Drug Makers To See Value In Mobile Apps
Firms May Lose Data Exclusivity Earlier Under Planned EU Adaptive Licensing Regime
EFPIA Calls For Increased EU Collaboration Ahead Of European Elections
G8 Agrees World Will Tackle Alzheimer’s, But Solutions Are Some Way Off
EU’s IMI, Drug Makers And Universities Join In New R&D Effort
European Regulatory Round-Up: Research Partners And Parallel Traders
European Regulatory Round-Up: Research Partners And Parallel Traders

Topics

Advertisement
UsernamePublicRestriction

Register

PS052941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel